Skip to main navigation Skip to search Skip to main content

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma

  • Pengcheng He
  • , Haibo Liu
  • , Bryan Zimdahl
  • , Jie Wang
  • , Minna Luo
  • , Qi Chang
  • , Fangzhou Tian
  • , Fan Ni
  • , Duo Yu
  • , Huasheng Liu
  • , Limei Chen
  • , Huaiyu Wang
  • , Mei Zhang
  • , Stephan A. Grupp
  • , Cheng Liu
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • Eureka Therapeutics
  • University of Pennsylvania
  • Children's Hospital of Philadelphia

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Purpose: A barrier to widespread adoption of chimeric antigen receptor (CAR) T-cell therapy is toxicity. To address this, we recently developed a novel antibody-T-cell receptor (AbTCR) platform (trademarked as ARTEMIS®) which was designed to leverage natural immune receptor signaling and regulation. The AbTCR platform includes a gamma/delta (γδ) TCR-based AbTCR construct and a separate co-stimulatory molecule, both engineered to be tumor-specific. Here, we aim to assess the safety and preliminary efficacy of a CD19-directed AbTCR T-cell therapy. Methods: We generated ET019003 T cells, which are autologous CD19-directed AbTCR T cells. We then conducted an early phase I study to evaluate the safety and preliminary efficacy of ET019003 T cells for the treatment of CD19-positive relapsed/refractory (r/r) B-cell lymphoma. Results: Sixteen patients enrolled in this study and 12 patients were treated. Of the 12 patients treated, 6 patients (50%) achieved a complete response (CR), and 4 (33%) achieved a partial response (PR) (best objective response rate [ORR] of 83%). CRs were durable, including 2 patients with ongoing CRs for 22.7 months and 23.2 months. ET019003 was well-tolerated with an attractive safety profile. No patients experienced severe (grade ≥ 3) cytokine release syndrome (CRS) and only 1 patient experienced immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade. Significant elevations of cytokine levels were not seen, even in patients with marked expansion of ET019003 T cells. Conclusion: This study provides initial clinical validation of the AbTCR platform as a novel cancer treatment with the potential to provide durable clinical benefit with low toxicity. Trial registration: NCT03642496; Date of registration: August 22, 2018.

Original languageEnglish
Pages (from-to)2757-2769
Number of pages13
JournalJournal of Cancer Research and Clinical Oncology
Volume149
Issue number7
DOIs
StatePublished - Jul 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Antibody-T-cell receptor therapy
  • B-cell lymphoma
  • CD19-directed therapy
  • Immunotherapy
  • T-cell therapy

Fingerprint

Dive into the research topics of 'A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma'. Together they form a unique fingerprint.

Cite this